New Drug Shows Promise Against Alzheimer’s
Good news, a New Alzheimer’s Drug shows promise. First, there has been many failures in Alzheimer’s drugs. Finally, there may be a medication that has shown positive outcomes. For example, it has some success in clearing out the toxic amyloid proteins. Thus, a significant slowing of the rate of the individuals patient’s cognitive decline. Biogen and Eisai announced a new experimental drug, “BAN240”. The New Alzheimer’s drug has shown some encouraging results.
A news release touting their results
Last week they released the data results that everyone was waiting for. However, there was cautious optimism at the Alzheimer’s Association International Conference in Chicago. The company showed a study of patinets over 1 1/2 years. First, the new Alzheimer’s drug was given in the highest dose possible.The dose, 10 mg per kilogram of body weight . Second, the dose was administered 2 times a month. Third, the medication was given through a IV. Hence, big impact on patients with mild cognitive impairment and early Alzheimer’s disease. For example, large reductions of beta amyloid. They had about 92.9 percent less beta amyloid. In contrast, individuals men and women receive a placebo. Finally, is showed a lesser level on cognitive tests than patients who were taking a type of placebo.
The New Alzheimer’s drug also has dome negative side effects
First 13-16 Percent of patients on the highest dose of the drug patents had some negative side effects. Second, some of the negative side effects were serious. However, 16% of people on placebos had some negative side effects. For example, brain swelling related to removal of amyloid from the brain. Again, a phenomenon refereed to as ARIA-E. Most ARIA didn’t cause problems. To sum up, 9-10% had headaches, visual disturbances, as well as types of confusion. Hence, the New Alzheimer’s Drug is the light at the end of the tunnel.
Beta amyloid protein is the primary component of sticky plaques which builds up in the brain
It’s considered a signature, and a likely cause, of the disease. “Beta amyloid is in everyone’s’ brain. Hence, it is a perfectly normal protein. This being said, the new Alzheimer’s drug helps keep this in check. To sum up, disease, the body’s normal process for getting beta amyloid out of the brain stops working properly. The results, Alzheimer’s or dementia can be helped with the New Alzheimer’s Drug.
Usually, beta amyloid gets cut out by an enzyme called alpha secretase. The two pieces get cleared from the brain and everything is OK, In Alzheimer’s disease, two other enzymes–beta secretase and gamma secretase–cut the protein in places it wouldn’t normally be, leaving fragments that the body doesn’t recognize or know how to get rid of, he says.
Possible Next Steps in treating Alzheimer’s
The pharma company presented BAN2401 data to regulatory authorities like the FDA. There has been no commitment for the beginning of a phase 3 trial. Hence, the final steps before the new Alzheimer’s drug receiving regulatory approval. Med-Q Medication Compliance System syas it’s encouraging to see positive results. However, lot more research ought to be done. This new drug can be a miracle. Hence will this new New Alzheimer’s Drug help millions.
First of all, these toxic fragments will begin to accumulate and start to form plaques. . The new Alzheimer’s drug is particularly good at breaking down the toxic beta amyloid fragments. These fragments are called protofibrils. The new drug originated from a family in a small town in the country of Sweden. This unique family had an inherited genetic mutation. The mutation has been labeled the Arctic mutation. The mutation leads to elevated levels of protofibrils in their brains. Hence, at ay high risk for developing Alzheimer’s or dementia. Researchers are guessing that clearing these toxic fragments may help. Finally, it shows BAN2401 was effective at removing beta amyloid.
No drug has ever demonstrated both the ability to clear beta amyloid and slow the progression of the disease in such a short period of time, The Alzheimer’s Association said the research indicates “that amyloid remains an important therapeutic target to pursue in Alzheimer’s disease. To sum up, the jury is still out on whether that will be the miracle cure that is being looked for.
Your Content Goes Here